One study (48) showed that HMGCR moderate/strong expression was associated with prognostically adverse tumour characteristics (higher histological grade, high Ki67, and ER negativity) and that neither HMGCR expression nor statin use was associated with breast cancer mortality (48). This evidence concerns the gene ESR1 and breast carcinoma.